FindTrial
Sign In

Priorix

BIOLOGICAL7 trials

Sponsors

GlaxoSmithKline, Sanofi

Conditions

Infections, PapillomavirusMeaslesMeasles-Mumps-RubellaMeasles-Mumps-Rubella VaccineMeasles; Mumps; RubellaMumpsPneumococcal ImmunizationRubella

Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
CompletedNCT01621802
GlaxoSmithKlineMeasles-Mumps-Rubella
Start: 2012-06-21End: 2015-11-09Updated: 2019-11-25
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
CompletedNCT01627561
GlaxoSmithKlineInfections, Papillomavirus
Start: 2012-10-15End: 2016-10-06Updated: 2020-04-10
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
CompletedNCT01681992
GlaxoSmithKlineMeasles, Measles-Mumps-Rubella Vaccine, Mumps +1
Start: 2012-10-10End: 2015-08-18Updated: 2021-01-07
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
CompletedNCT01702428
GlaxoSmithKlineMeasles, Mumps, Rubella
Start: 2012-11-09End: 2015-04-16Updated: 2019-11-25
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
CompletedNCT02184572
GlaxoSmithKlineMeasles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Start: 2014-08-25End: 2015-12-22Updated: 2021-01-07
Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Active, not recruitingNCT06824181
SanofiPneumococcal Immunization
Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
RecruitingNCT06824194
SanofiPneumococcal Immunization
Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03

Related Papers

Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus–16/18 Vaccine in Four- to Six-year-old Girls
The Pediatric Infectious Disease Journal2019-08-3014 citations
Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates
The Journal of Infectious Diseases2019-07-1012 citations
Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study
Journal of the Pediatric Infectious Diseases Society2019-02-2817 citations
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration
Human Vaccines & Immunotherapeutics2019-02-2014 citations
Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study
Human Vaccines & Immunotherapeutics2018-08-1710 citations
Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
2018-08-109 citations
Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls: Results to Month 12 From a Randomized Trial.
2018-04-017 citations